Trial Profile
A Phase 1, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of FG-4592 in Subjects With Moderate Hepatic Impairment and Healthy Subjects With Normal Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Pharmacokinetics
- Sponsors Astellas Pharma Europe Ltd
- 28 Jun 2016 Results published in the Clinical Drug Investigation
- 17 Jun 2014 New trial record